Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Seelos Therapeutics' SLS-004 shows significant efficacy in dementia » 08:05
06/09/22
06/09
08:05
06/09/22
08:05
SEEL

Seelos Therapeutics

/

+

Seelos Therapeutics…

Seelos Therapeutics announced data demonstrating a statistically significant - pless than0.01 - 19% downregulation of mRNA and a ~40% reduction of alpha synuclein in an in vitro study of SLS-004, its gene therapy program utilizing CRISPR-dCas9, in dementia with Lewy bodies, or DLB. DLB is characterized by the accumulation of aggregated alpha-synuclein protein in Lewy bodies and Lewy neurites. Seelos plans to advance into additional preclinical studies in DLB and Parkinson's and expects additional data in the second half of this year. Seelos plans to advance the study of SLS-004 in DLB in additional preclinical studies and disclose further developments of this new CRISPR-based therapeutic technology in the future. In July 2021, Seelos released positive preclinical in vivo data with SLS-004 in downregulation of overexpressed alpha-synuclein in a Parkinson's disease model and plans to release additional data in the second half of 2022.

ShowHide Related Items >><<
SEEL Seelos Therapeutics
/

+

SEEL Seelos Therapeutics
/

+

03/14/22 B. Riley
Seelos Therapeutics price target lowered to $4 from $6 at B. Riley
03/08/22 Cantor Fitzgerald
Seelos Therapeutics price target lowered to $3 from $5 at Cantor Fitzgerald
01/24/22 B. Riley
Seelos Therapeutics price target lowered to $6 from $11 at B. Riley
11/24/21 Benchmark
Seelos Therapeutics' license acquisition 'positive,' says Benchmark
SEEL Seelos Therapeutics
/

+

Over a month ago
Hot Stocks
Seelos Therapeutics receives Notice of Allowance for U.S. patent » 08:03
05/18/22
05/18
08:03
05/18/22
08:03
SEEL

Seelos Therapeutics

/

+

Seelos Therapeutics…

Seelos Therapeutics announced it has received a Notice of Allowance for U.S. patent application number 16/833,515 from the United States Patent and Trademark Office covering SLS-007 titled: "Structure-Based Peptide Inhibitors of Alpha-Synuclein Aggregation". This Notice of Allowance covers the method of treating several neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Lewy body dementia and multiple system atrophy, through contacting alpha-synuclein protofilaments with an effective amount of SLS-007. Seelos is currently delivering SLS-007 via an adeno-associated virus in a preclinical study designed to establish the in vivo pharmacokinetic and pharmacodynamic profiles and target engagement. SLS-007 is comprised of endogenously available amino acids and thus is expected to be a novel approach to target prevention of alpha-synuclein aggregation and slow disease progression in synucleinopathy diseases. Preliminary data from the study is expected in the second half of 2022.

ShowHide Related Items >><<
SEEL Seelos Therapeutics
/

+

SEEL Seelos Therapeutics
/

+

03/14/22 B. Riley
Seelos Therapeutics price target lowered to $4 from $6 at B. Riley
03/08/22 Cantor Fitzgerald
Seelos Therapeutics price target lowered to $3 from $5 at Cantor Fitzgerald
01/24/22 B. Riley
Seelos Therapeutics price target lowered to $6 from $11 at B. Riley
11/24/21 Benchmark
Seelos Therapeutics' license acquisition 'positive,' says Benchmark
  • 20
    May
SEEL Seelos Therapeutics
/

+

Conference/Events
B. Riley to hold a virtual conference » 10:06
04/27/22
04/27
10:06
04/27/22
10:06
SEEL

Seelos Therapeutics

/

+

, HROW

Harrow Health

$6.56 /

+0.22 (+3.47%)

, CGTX

Cognition Therapeutics

$2.83 /

-0.035 (-1.22%)

, FREQ

Frequency Therapeutics

$1.40 /

+0.005 (+0.36%)

, IKT

Inhibikase Therapeutics

$1.11 /

+ (+0.00%)

, MNOV

MediciNova

$2.65 /

-0.095 (-3.46%)

, NGM

NGM Biopharmaceuticals

$14.82 /

+0.21 (+1.44%)

, SRNE

Sorrento Therapeutics

$1.61 /

-0.005 (-0.31%)

, TNXP

Tonix Pharmaceuticals

/

+

Annual Neuro &…

Annual Neuro & Ophthalmology Virtual Investor Conference to be held on April 27.

ShowHide Related Items >><<
TNXP Tonix Pharmaceuticals
/

+

SRNE Sorrento Therapeutics
$1.61 /

-0.005 (-0.31%)

SEEL Seelos Therapeutics
/

+

NGM NGM Biopharmaceuticals
$14.82 /

+0.21 (+1.44%)

MNOV MediciNova
$2.65 /

-0.095 (-3.46%)

IKT Inhibikase Therapeutics
$1.11 /

+ (+0.00%)

HROW Harrow Health
$6.56 /

+0.22 (+3.47%)

FREQ Frequency Therapeutics
$1.40 /

+0.005 (+0.36%)

CGTX Cognition Therapeutics
$2.83 /

-0.035 (-1.22%)

SEEL Seelos Therapeutics
/

+

03/14/22 B. Riley
Seelos Therapeutics price target lowered to $4 from $6 at B. Riley
03/08/22 Cantor Fitzgerald
Seelos Therapeutics price target lowered to $3 from $5 at Cantor Fitzgerald
01/24/22 B. Riley
Seelos Therapeutics price target lowered to $6 from $11 at B. Riley
11/24/21 Benchmark
Seelos Therapeutics' license acquisition 'positive,' says Benchmark
HROW Harrow Health
$6.56 /

+0.22 (+3.47%)

10/14/21 B. Riley
Harrow Health resumed with a Buy at B. Riley
10/14/21 B. Riley
Harrow Health resumed with a Buy at B. Riley
10/14/21 B. Riley
Harrow Health resumed with a Buy at B. Riley
09/23/21 Aegis
Harrow Health initiated with a Buy at Aegis
CGTX Cognition Therapeutics
$2.83 /

-0.035 (-1.22%)

04/22/22 Ladenburg
Cognition Therapeutics initiated with a Buy at Ladenburg
01/24/22 B. Riley
Cognition Therapeutics price target lowered to $20 from $27 at B. Riley
11/03/21
Fly Intel: Top five analyst initiations
11/03/21 B. Riley
Cognition Therapeutics initiated with a Buy at B. Riley
FREQ Frequency Therapeutics
$1.40 /

+0.005 (+0.36%)

03/23/22 B. Riley
Frequency Therapeutics price target lowered to $10 from $17 at B. Riley
01/24/22 B. Riley
Frequency Therapeutics price target lowered to $17 from $21 at B. Riley
09/22/21 Goldman Sachs
Frequency Therapeutics downgraded to Neutral from Buy at Goldman Sachs
05/17/21 B. Riley
Frequency Therapeutics price target lowered to $21 from $35 at B. Riley
IKT Inhibikase Therapeutics
$1.11 /

+ (+0.00%)

07/15/21 JonesTrading
Inhibikase Therapeutics initiated with a Buy at JonesTrading
MNOV MediciNova
$2.65 /

-0.095 (-3.46%)

01/24/22 B. Riley
MediciNova price target lowered to $6 from $11 at B. Riley
NGM NGM Biopharmaceuticals
$14.82 /

+0.21 (+1.44%)

03/02/22 Raymond James
NGM Biopharmaceuticals downgraded to Outperform from Strong Buy at Raymond James
01/07/22 Piper Sandler
NGM Biopharmaceuticals price target raised to $32 from $30 at Piper Sandler
09/16/21 BMO Capital
NGM Biopharmaceuticals price target raised to $35 from $29 at BMO Capital
09/12/21 Raymond James
NGM Biopharmaceuticals upgraded to Strong Buy from Outperform at Raymond James
SRNE Sorrento Therapeutics
$1.61 /

-0.005 (-0.31%)

03/25/22 H.C. Wainwright
Sorrento Therapeutics price target lowered to $20 from $26 at H.C. Wainwright
12/28/21 H.C. Wainwright
H.C. Wainwright reiterates $26 target on Sorrento after Covistix news
08/09/21 H.C. Wainwright
Sorrento Therapeutics price target lowered to $26 from $30 at H.C. Wainwright
TNXP Tonix Pharmaceuticals
/

+

04/18/22 Noble Capital
Tonix Pharmaceuticals initiated with an Outperform at Noble Capital
08/31/21 Alliance Global Partners
Alliance Global Partners ups Tonix target to $3 amid NIH interest in Long-COVID
08/11/21 Alliance Global Partners
Tonix Pharmaceuticals price target lowered to $2 from $4 at Alliance Global Partners
TNXP Tonix Pharmaceuticals
/

+

NGM NGM Biopharmaceuticals
$14.82 /

+0.21 (+1.44%)

HROW Harrow Health
$6.56 /

+0.22 (+3.47%)

FREQ Frequency Therapeutics
$1.40 /

+0.005 (+0.36%)

CGTX Cognition Therapeutics
$2.83 /

-0.035 (-1.22%)

  • 08
    Oct
  • 16
    Jun
  • 20
    May
SRNE Sorrento Therapeutics
$1.61 /

-0.005 (-0.31%)

HROW Harrow Health
$6.56 /

+0.22 (+3.47%)

CGTX Cognition Therapeutics
$2.83 /

-0.035 (-1.22%)

SRNE Sorrento Therapeutics
$1.61 /

-0.005 (-0.31%)

SEEL Seelos Therapeutics
/

+

Options
Seelos Therapeutics options imply 8.9% move in share price post-earnings » 13:49
04/22/22
04/22
13:49
04/22/22
13:49
SEEL

Seelos Therapeutics

/

+

Pre-earnings options…

Pre-earnings options volume in Seelos Therapeutics is normal with puts leading calls 7:6. Implied volatility suggests the market is anticipating a move near 8.9%, or 0c, after results are released. Median move over the past eight quarters is 4.4%.

ShowHide Related Items >><<
SEEL Seelos Therapeutics
/

+

SEEL Seelos Therapeutics
/

+

03/14/22 B. Riley
Seelos Therapeutics price target lowered to $4 from $6 at B. Riley
03/08/22 Cantor Fitzgerald
Seelos Therapeutics price target lowered to $3 from $5 at Cantor Fitzgerald
01/24/22 B. Riley
Seelos Therapeutics price target lowered to $6 from $11 at B. Riley
11/24/21 Benchmark
Seelos Therapeutics' license acquisition 'positive,' says Benchmark
  • 20
    May
SEEL Seelos Therapeutics
/

+

Hot Stocks
Seelos Therapeutics announces amendment of SLS-002 agreement » 08:13
04/11/22
04/11
08:13
04/11/22
08:13
SEEL

Seelos Therapeutics

/

+

Seelos Therapeutics…

Seelos Therapeutics announced an amendment of the agreement with Phoenixus AG, formerly known as Vyera Pharmaceuticals AG, for the development of SLS-002 to repurchase in cash and stock the remaining royalties payable on any future net sales of SLS-002, all future success and commercial based milestones and the change of control fee in the event SLS-002 is acquired. On March 6, 2018, Seelos entered into an asset purchase agreement (the "Purchase Agreement") with Vyera, currently known as Phoenixus AG, to acquire the assets and liabilities of Vyera's intranasal racemic ketamine program, which Seelos now calls SLS-002. As additional consideration to certain upfront cash and equity payments and success-based milestone payments contemplated under the prior agreement, Seelos agreed to pay a mid-teens percentage royalty on any future net sales of SLS-002. In February 2021, Seelos amended the asset purchase agreement, for three additional cash payments, agreeing to repurchase 9% of the future royalties and reduce its royalty obligations to a mid-single digit percentage on any future net sales of SLS-002. Seelos completed those payments in February, June, and September of 2021. Under the amendment entered into on April 8, 2022, for additional cash and stock payments due by April 2022, July 2022 and January 2023, the parties have agreed to terminate in full all contingent payment obligations to Vyera and its related entities under the Purchase Agreement, effective upon the payment and issuance of all cash and stock payments. "This amendment removes all future royalties due to Vyera, nearly $100 million of potential future milestones and a change of control fee in the event this program were to be acquired as a standalone transaction or as part of a larger transaction," said Michael Golembiewski, CFO of Seelos.

ShowHide Related Items >><<
SEEL Seelos Therapeutics
/

+

SEEL Seelos Therapeutics
/

+

03/14/22 B. Riley
Seelos Therapeutics price target lowered to $4 from $6 at B. Riley
03/08/22 Cantor Fitzgerald
Seelos Therapeutics price target lowered to $3 from $5 at Cantor Fitzgerald
01/24/22 B. Riley
Seelos Therapeutics price target lowered to $6 from $11 at B. Riley
11/24/21 Benchmark
Seelos Therapeutics' license acquisition 'positive,' says Benchmark
  • 20
    May
  • 20
    Apr
SEEL Seelos Therapeutics
/

+

Over a quarter ago
Conference/Events
Seelos Therapeutics management to meet with Benchmark » 04:55
03/24/22
03/24
04:55
03/24/22
04:55
SEEL

Seelos Therapeutics

/

+

Research Analyst Jackson…

Research Analyst Jackson holds a meeting with Anthony Marciano, Communications Director, in Stamford/Greenwich, CT on March 24 hosted by Benchmark.

ShowHide Related Items >><<
SEEL Seelos Therapeutics
/

+

SEEL Seelos Therapeutics
/

+

03/14/22 B. Riley
Seelos Therapeutics price target lowered to $4 from $6 at B. Riley
03/08/22 Cantor Fitzgerald
Seelos Therapeutics price target lowered to $3 from $5 at Cantor Fitzgerald
01/24/22 B. Riley
Seelos Therapeutics price target lowered to $6 from $11 at B. Riley
11/24/21 Benchmark
Seelos Therapeutics' license acquisition 'positive,' says Benchmark
  • 20
    May
  • 20
    Apr
SEEL Seelos Therapeutics
/

+

Conference/Events
Seelos Therapeutics management to meet with Benchmark » 15:45
03/21/22
03/21
15:45
03/21/22
15:45
SEEL

Seelos Therapeutics

/

+

Research Analyst Jackson…

Research Analyst Jackson holds a meeting with Anthony Marciano, Communications Director, in Stamford/Greenwich, CT on March 24 hosted by Benchmark.

ShowHide Related Items >><<
SEEL Seelos Therapeutics
/

+

SEEL Seelos Therapeutics
/

+

03/14/22 B. Riley
Seelos Therapeutics price target lowered to $4 from $6 at B. Riley
03/08/22 Cantor Fitzgerald
Seelos Therapeutics price target lowered to $3 from $5 at Cantor Fitzgerald
01/24/22 B. Riley
Seelos Therapeutics price target lowered to $6 from $11 at B. Riley
11/24/21 Benchmark
Seelos Therapeutics' license acquisition 'positive,' says Benchmark
  • 20
    May
  • 20
    Apr
SEEL Seelos Therapeutics
/

+

Recommendations
Seelos Therapeutics price target lowered to $4 from $6 at B. Riley » 07:46
03/14/22
03/14
07:46
03/14/22
07:46
SEEL

Seelos Therapeutics

/

+

B. Riley analyst Mayank…

B. Riley analyst Mayank Mamtani lowered the firm's price target on Seelos Therapeutics to $4 from $6 and keeps a Buy rating on the shares. The analyst dropped the price target to account for higher cost of capital to support the company's relatively higher operating expenditure ramp.

ShowHide Related Items >><<
SEEL Seelos Therapeutics
/

+

SEEL Seelos Therapeutics
/

+

03/08/22 Cantor Fitzgerald
Seelos Therapeutics price target lowered to $3 from $5 at Cantor Fitzgerald
01/24/22 B. Riley
Seelos Therapeutics price target lowered to $6 from $11 at B. Riley
11/24/21 Benchmark
Seelos Therapeutics' license acquisition 'positive,' says Benchmark
10/21/21 B. Riley
Seelos shares offer 'significant potential upside optionality,' says B. Riley
  • 20
    May
  • 20
    Apr
SEEL Seelos Therapeutics
/

+

Hot Stocks
Seelos Therapeutics receives letter of CTN from Australian TGA for SLS-005 » 08:03
03/08/22
03/08
08:03
03/08/22
08:03
SEEL

Seelos Therapeutics

/

+

Seelos Therapeutics…

Seelos Therapeutics announced it has received an acknowledgement letter of a Clinical Trial Notification, or CTN, from the Australian Government Department of Health Therapeutic Goods Administration, or TGA, for a pilot study of SLS-005, or trehalose injection, 90.5 mg/mL for intravenous infusion, for the treatment of patients with Alzheimer's disease. In addition, Seelos received authorization to conduct a separate open-label basket study in Australia to evaluate the effectiveness of SLS-005 on disease progression and severity, as well as its safety and tolerability, in participants with selected neurodegenerative diseases including Huntington's disease.

ShowHide Related Items >><<
SEEL Seelos Therapeutics
/

+

SEEL Seelos Therapeutics
/

+

03/08/22 Cantor Fitzgerald
Seelos Therapeutics price target lowered to $3 from $5 at Cantor Fitzgerald
01/24/22 B. Riley
Seelos Therapeutics price target lowered to $6 from $11 at B. Riley
11/24/21 Benchmark
Seelos Therapeutics' license acquisition 'positive,' says Benchmark
10/21/21 B. Riley
Seelos shares offer 'significant potential upside optionality,' says B. Riley
  • 20
    May
  • 20
    Apr
SEEL Seelos Therapeutics
/

+

Recommendations
Seelos Therapeutics price target lowered to $3 from $5 at Cantor Fitzgerald » 07:10
03/08/22
03/08
07:10
03/08/22
07:10
SEEL

Seelos Therapeutics

/

+

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Charles Duncan lowered the firm's price target on Seelos Therapeutics to $3 from $5 and keeps an Overweight rating on the shares. The price target reduction is a result of the challenging sentiment in the biotech sector, especially for companies with limited cash resources and high-risk programs, Duncan tells investors in a research note.

ShowHide Related Items >><<
SEEL Seelos Therapeutics
/

+

SEEL Seelos Therapeutics
/

+

01/24/22 B. Riley
Seelos Therapeutics price target lowered to $6 from $11 at B. Riley
11/24/21 Benchmark
Seelos Therapeutics' license acquisition 'positive,' says Benchmark
10/21/21 B. Riley
Seelos shares offer 'significant potential upside optionality,' says B. Riley
09/27/21 Roth Capital
Seelos Therapeutics upgraded to Buy from Neutral at Roth Capital
  • 20
    May
  • 20
    Apr
SEEL Seelos Therapeutics
/

+

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.